The upside case is not about selling more robots alone; it is about turning density, verified execution, and hospital workflow embedding into a better revenue mix. If that happens, the market can value the business as an early physical-autonomy network rather than a speculative hardware story. I cap the outcome below cleaner software or infrastructure names because partner concentration, service mix, and
dilution risk still limit the
re-rating.